D341 Med Xenograft Model Service for Medulloblastoma

The D341 Med xenograft model is a well-established preclinical platform for studying medulloblastoma, the most common malignant pediatric brain tumor, enabling robust evaluation of novel therapeutic strategies in an in vivo setting. At Alfa Cytology, we specialize in delivering high-quality, reproducible D341 Med xenograft model services tailored to your drug discovery and preclinical development needs, with comprehensive endpoint analysis and customizable study designs to accelerate your research pipeline.

Overview of D341 Med Xenograft Model for Medulloblastoma

Medulloblastoma is a highly malignant embryonal tumor of the cerebellum, predominantly affecting children, and represents the most frequent malignant brain tumor in the pediatric population. The D341 Med cell line, established in 1988 from tumor tissue of a 3.5-year-old male patient, has become one of the most widely utilized models in medulloblastoma research. This cell line belongs to Group 3 medulloblastoma, the most aggressive molecular subgroup, characterized by MYC amplification and isochromosome 17q, which are associated with poor prognosis and high metastatic potential. D341 Med cells grow in suspension culture with spontaneous macroscopic spheroid formation, mimicking the three-dimensional tumor microenvironment and providing a physiologically relevant platform for preclinical studies.

When injected into immunodeficient athymic nude mice, D341 Med cells form serially transplantable tumors both subcutaneously and intracranially. Subcutaneous xenografts develop as markedly cellular, highly invasive undifferentiated neoplasms, while intracranial tumors grow as mitotically active neoplasms largely located within the subarachnoid space or lining the ventricular system. The D341 Med xenograft model has been extensively employed in preclinical studies to evaluate the efficacy of multi-kinase inhibitors, proteasome inhibitors, and novel targeted therapies, bridging the gap between in vitro findings and translational application. Its well-defined molecular profile and reproducible tumorigenicity make it an indispensable tool for understanding medulloblastoma biology and accelerating therapeutic development.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting Group 3 medulloblastoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving medulloblastoma progression and MYC-driven oncogenic signaling, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. The expression of Syk in D341 and Daoy cell lines of human medulloblastoma. (Zhou, Kaiyu, et al., 2019)

Cell Line Information: D341 Med

The D341 Med cell line is a continuous human medulloblastoma cell line with well-characterized phenotypic, genotypic, and tumorigenic properties. Its classification within Group 3 medulloblastoma and retention of spontaneous spheroid formation capacity makes it unique among available medulloblastoma cell lines and essential for preclinical research targeting the most aggressive pediatric brain tumor subtype.

Our Services

Alfa Cytology provides comprehensive, end-to-end D341 Med xenograft model services designed to support your preclinical research objectives. Our experienced team manages every phase of the study---from cell line authentication and quality control to tumor monitoring, treatment administration, and endpoint analysis---ensuring reliable, publication-ready data. Whether you require standard subcutaneous xenografts, orthotopic intracranial models, or customized study protocols with specific endpoints, Alfa Cytology delivers flexible, high-quality solutions that align with your drug development timeline and scientific goals.

Workflow of D341 Med Xenograft Model Construction

The construction of a D341 Med xenograft model follows a standardized, multi-step workflow that ensures reproducible tumor growth, ethical compliance, and reliable data generation. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Authentication and Quality Control: D341 Med cells are authenticated via STR profiling and tested for mycoplasma contamination prior to expansion. Cells are maintained in suspension culture under optimal conditions (EMEM + 10% FBS, 37 degrees C, 5% CO2) and harvested during the logarithmic growth phase to ensure high viability for implantation.
2. Animal Preparation and Ethical Approval: Immunodeficient athymic nude mice (nu/nu, 6--8 weeks old) are acclimatized under pathogen-free conditions in laminar flow isolators with autoclaved food and water. All procedures are conducted in accordance with institutional animal ethics committee approvals and international guidelines (e.g., EU Directive 2010/63/EU).
3. Tumor Cell Preparation and Matrigel Mixing: Harvested D341 Med cells are counted, viability is confirmed (typically >95%), and cells are resuspended at the desired concentration (commonly 6 x 10^6 cells per 200 uL) in a 1:1 mixture of serum-free medium and Matrigel (BD Biosciences) to enhance tumor take rate and engraftment efficiency.
4. Xenograft Implantation: For subcutaneous models, the cell suspension is injected into the flank of the mouse using a sterile syringe. For orthotopic intracranial models, stereotactic injection is performed to deliver cells directly into the cerebellar region, recapitulating the anatomical origin of medulloblastoma and enabling assessment of tumor invasion and leptomeningeal dissemination.
5. Tumor Monitoring and Randomization: Mice are monitored daily for health status, and tumor dimensions are measured with calipers twice weekly. Tumor volume is calculated using the formula: length x width^2 / 2. Once tumors reach approximately 100--200 mm^3, animals are randomized into treatment and control groups to ensure statistical balance.
6. Treatment Administration and Endpoint Analysis: Test compounds are administered according to the study protocol (e.g., oral gavage, intraperitoneal, or intravenous injection). Tumor growth, body weight, and survival are monitored throughout the study. At endpoint, tumors are excised, weighed, and processed for histopathology, immunohistochemistry, biomarker analysis, and molecular profiling.

Figure 2: Schematic workflow illustrating the derivation and construction of the D341 Med Xenograft Model at Alfa Cytology.

Case Study-D341 Med Xenograft Model Development

Alfa Cytology has successfully developed and validated D341 Med xenograft models for multiple preclinical drug development programs targeting medulloblastoma. In a representative study, D341 Med cells were engrafted into immunodeficient mice, achieving consistent tumor take rates with reproducible growth kinetics. Treatment arms evaluated candidate compounds across various dosing regimens, with comprehensive endpoint analysis including tumor growth inhibition, survival benefit, pharmacokinetic profiling, and histopathological examination. Detailed datasets and study reports are available upon request for qualified research partners.

Why Choose Alfa Cytology?

Alfa Cytology is your trusted partner for preclinical medulloblastoma research, offering scientifically rigorous, ethically compliant, and highly customizable D341 Med xenograft model services. Our integrated platform combines expertise in tumor biology, animal model development, and comprehensive endpoint analysis to deliver actionable insights for your drug discovery pipeline.

• Verified Cell Line Integrity: Extensive experience with D341 Med and other medulloblastoma cell lines, ensuring optimized engraftment and reproducible tumor growth.
• High Take Rates and Consistency: Fully validated cell lines with STR authentication, mycoplasma testing, and quality-controlled expansion protocols.
• Comprehensive Analytical Support: Flexible study designs including subcutaneous, orthotopic, and patient-derived xenograft (PDX) models with customizable endpoints.
• Tailored Study Designs: Comprehensive in-life monitoring, advanced imaging capabilities, and robust statistical analysis for publication-ready data.
• Standardized Protocols: Strict adherence to international animal welfare guidelines and institutional ethical review board approvals.
• Dedicated Project Management: Dedicated project management with transparent communication, timely reporting, and competitive turnaround times.

Contact Us

Ready to advance your medulloblastoma research with our D341 Med xenograft model services? Contact us today to discuss your project requirements, receive a customized study proposal, and learn how Alfa Cytology can accelerate your preclinical development pipeline. Please reach out to us today via our inquiry form or email to learn more about our D341 Med Xenograft Model services.

For research use only. Not intended for any clinical use.